Literature DB >> 15385830

Quetiapine serum concentrations in psychiatric patients: the influence of comedication.

Jørgen Hasselstrøm1, Kristian Linnet.   

Abstract

Steady-state serum concentrations of quetiapine were recorded in 62 psychiatric patients under routine conditions. Doses were administered twice daily, and serum quetiapine levels were measured in the morning about 12 hours after the last dose. Eight patients were in monotherapy, whereas the rest received various additional psychotropic drugs. For the whole group, the concentration-to-dose ratio (C/D) varied 238-fold, with a median value of 0.41 nmol/L/(mg/24 h). For the administered dose range (37.5-1200 mg/24 h), the serum concentrations ranged from below the detection limit (10 nmol/L) to 999 nmol/L. With the exception of 2 subjects receiving carbamazepine and patients receiving quetiapine outside the recommended dose interval, 80% of the rest had serum levels within the range 50 to 650 nmol/L, which may serve as an orienting interval for serum concentrations observed under routine treatment conditions. Patients (n = 38) comedicated with drugs competing for metabolism by CYP3A4 displayed a median C/D value of 0.48 nmol/L/(mg/24 h), which was 70% higher than the C/D value of the monotherapy group [0.28 nmol/L/(mg/24 h)], in contrast to patients receiving drugs metabolized by CYP2D6 with a median C/D of 0.23 nmol/L/(mg/24 h). None of the comedicated groups were significantly different from the monotherapy group. Two subjects comedicated with carbamazepine had very low C/D values [0.02-0.04 nmol/L/(mg/24 h)].

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385830     DOI: 10.1097/00007691-200410000-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  7 in total

Review 1.  [Differences between men and women in side effects of second-generation antipsychotics].

Authors:  W Aichhorn; A B Whitworth; E M Weiss; H Hinterhuber; J Marksteiner
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

Review 2.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Authors:  Massimo Carlo Mauri; Silvia Paletta; Chiara Di Pace; Alessandra Reggiori; Giovanna Cirnigliaro; Isabel Valli; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

Review 3.  Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

Authors:  Wolfgang Aichhorn; Alexandra B Whitworth; Elisabeth M Weiss; Josef Marksteiner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects.

Authors:  Magdalena Nord; Svante Nyberg; Jacob Brogren; Aurelija Jucaite; Christer Halldin; Lars Farde
Journal:  Int J Neuropsychopharmacol       Date:  2011-04-11       Impact factor: 5.176

5.  Plasma quetiapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2000-2011.

Authors:  Simon A Handley; Sally V J Bowskill; Maxine X Patel; Robert J Flanagan
Journal:  Ther Adv Psychopharmacol       Date:  2013-06

6.  Coma After Quetiapine Fumarate Intentional Overdose in a 71-year-old Man: A Case Report.

Authors:  S Gibiino; A Trappoli; B Balzarro; A R Atti; D De Ronchi
Journal:  Drug Saf Case Rep       Date:  2015-12

7.  Overdose of Quetiapine-A Case Report with QT Prolongation.

Authors:  Elisabetta Bertol; Fabio Vaiano; Antonina Argo; Stefania Zerbo; Claudia Trignano; Simone Protani; Donata Favretto
Journal:  Toxics       Date:  2021-12-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.